Statins in the Prevention and Treatment of Alzheimer Disease
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD). Treatment of hypercholesterolemia and other vascular risk factors may have great implications in the prevention of AD. Recent findings illustrate that the sterol metabolism in the brain is an active process, well controlled and regulated by 24-hydroxylase, an enzyme that is uniquely expressed in the brain. The use of statins in ischemic heart disease (IHD) has proven to be a phenomenal advance in pharmacological disease prevention and treatment. A growing body of evidence, suggest that statins exhibit additional benefits that are independent of their cholesterol-lowering actions. Statin treatment has also considerable effect in prevention of ischemic stroke. In animal models of ischemic stroke, statins have proven to reduce infarct size through up-regulation of endothelial nitric oxide synthases. Data from recent observational studies have revealed a potential role for statins in prevention of AD. The following review comments the processes leading to dementia including the involvement of cholesterol regulation, cerebral circulation and inflammation in development of dementia. The mechanisms by which statins may be beneficial in controlling these processes is discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Kivipelto, M., Helkala, E.-L., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Soininen, H., Tuomilehto, J., & Nissinen, A. (2001) · BMJ · doi:10.1136/bmj.322.7300.1447 · Cited by 1,618 · cited 1×
“A recent study by Kojro et al. (2001) demonstrates that cholesterol-extracting agents, such as methyl- -cyclodextrin and the HMG-CoA reductase inhibitor lovastatin, increase the level of -secretase cleaved soluble APP (APPs ) in various peripheral and neuronal cell lines.”
BackgroundRidker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F. M., Moye, L. A., Goldman, S., Flaker, G. C., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.9.839 · Cited by 1,389
Post-transcriptional Regulation of Endothelial Nitric Oxide Synthase mRNA Stability by Rho GTPase
Laufs, U., & Liao, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.24266 · Cited by 1,035 · cited 1×
“The hydrophobic A is a 40–42 amino acid proteolytic cleavage of amyloid precursor protein (APP) by -secretase and -secretase and is produced by neurons, microglia, astrocytes, and platelets (Kang et al., 1987; Haas et al., 1992; Li et al., 1998).”
BackgroundHoltzman, D. M., Bales, K. R., Tenkova, T., Fagan, A. M., Parsadanian, M., Sartorius, L. J., Mackey, B., Olney, J., McKeel, D., Wozniak, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050004797 · Cited by 937
Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10
Kojro, E., Gimpl, G., Lammich, S., März, W., & Fahrenholz, F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081612998 · Cited by 804
Lonn, E. M., Yusuf, S., Dzavik, V., Doris, C. I., Yi, Q., Smith, S., Moore-Cox, A., Bosch, J., Riley, W. A., & Teo, K. K. (2001) · Circulation · doi:10.1161/01.cir.103.7.919 · Cited by 712
β-Amyloid-mediated vasoactivity and vascular endothelial damage
Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M. (1996) · Nature · doi:10.1038/380168a0 · Cited by 703 · cited 1×
“A is shown to be cytotoxic to neurons, endothelial cells, and oligodendrocytes (Yanker et al., 1989; Thomas et al., 1996; Xu et al., 2001).”
BackgroundBjörkhem, I., Lütjohann, D., Diczfalusy, U., Ståhle, L., Ahlborg, G., & Wahren, J. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32188-x · Cited by 538
Cited by
Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease
Bartzokis, G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.03.001 · Cited by 968
“Furthermore, epidemiologic studies suggest that elevated peripheral cholesterol levels in midlife may predispose individuals to developing AD in old age [124], and medications which reduce cholesterol synthesis may be beneficial in preventing and possibly treating early AD [50,132,181,213,260,262] possibly by reversin…”
BackgroundE PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 515
Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature
Wagstaff, L. R., Mitton, M. W., Arvik, B. M., & Doraiswamy, P. M. (2003) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.871.32720 · Cited by 366
Statin Use and the Risk of Incident Dementia: The Cardiovascular Health Study
Rea, T. D., Breitner, J. C., Psaty, B. M., Fitzpatrick, A. L., Lopez, O. L., Newman, A. B., Hazzard, W. R., Zandi, P. P., Burke, G. L., Lyketsos, C. G., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1047 · Cited by 277
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Metadata
- Authors
- Crisby, M., Carlson, L. A., & Winblad, B.
- Venue
- Alzheimer Disease & Associated Disorders
- Published
- 2002-07
- Volume
- 16
- Issue
- 3
- Pages
- 131-136
- ISSN
- 0893-0341 (ISSN-L)
- OpenAlex
- W2094353481
- Cited by
- 91
- References
- 12
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins in the Prevention and Treatment of Alzheimer Disease. https://app.cochat.ai/papers/10.1097/00002093-200207000-00001
- The paper
- Crisby, M., Carlson, L. A., & Winblad, B. (2002). Statins in the Prevention and Treatment of Alzheimer Disease. Alzheimer Disease & Associated Disorders. https://doi.org/10.1097/00002093-200207000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.